Capricor Reportedly Exposed for Serious Flaws in Its Research; Company Responds: Follow-Up Arrangements to Be Announced After Assessment Is Completed
Capricor Therapeutics today announced that its resubmitted Biologics License Application for Deramiocel received a Complete Response Letter from the U.S. Food and Drug Administration. Deramiocel is an investigational cell therapy for the treatment of Duchenne muscular dystrophy. The Complete Response Letter stated that the FDA believes the existing data are insufficient to constitute substantial evidence of effectiveness, and also noted several other clinical deficiencies. The company's CEO said, "We are deeply disappointed for the boys and young men living with Duchenne muscular dystrophy and their families. Deramiocel has completed two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We are confident in the rigor of the clinical trial protocols and the integrity of the data, and believe the existing data support approval. We are carefully reviewing the letter and will announce next steps after completing our assessment." After news emerged that the FDA's inspection of Capricor found serious deficiencies in the Deramiocel studies, the company's stock fell 79% in after-hours trading.
Latest
9 m ago

